Use of glaucoma medications: State of the science and directions for observational research

American Journal of Ophthalmology

Volumn 150, Issue 4, 2010, Pages

  Lu, Vicky H ^a   Goldberg, Ivan ^a,b,c   Lu, Christine Y ^d  

^a SYDNEY EYE HOSPITAL   (Australia)

^b Eye Associates   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIMATOPROST; BRIMONIDINE; CARBONATE DEHYDRATASE INHIBITOR; DORZOLAMIDE PLUS TIMOLOL; LATANOPROST; LATANOPROST PLUS TIMOLOL; MIOTIC AGENT; PROSTAGLANDIN DERIVATIVE; TRAVOPROST; ANTIHYPERTENSIVE AGENT; EYE DROPS;

ARTICLE; COMORBIDITY; DATA BASE; DRUG CONTRAINDICATION; DRUG COST; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELECTRONIC MEDICAL RECORD; GLAUCOMA; HEALTH CARE POLICY; HUMAN; MEDICAL LITERATURE; MEDICAL RESEARCH; MONOTHERAPY; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT DURATION; CLINICAL PRACTICE; DRUG UTILIZATION; FACTUAL DATABASE; MEDICATION COMPLIANCE; OPHTHALMOLOGY; PHARMACY; STATISTICS AND NUMERICAL DATA;

ANTIHYPERTENSIVE AGENTS; DATABASES, FACTUAL; DRUG PRESCRIPTIONS; DRUG UTILIZATION; GLAUCOMA; HUMANS; MEDICATION ADHERENCE; OPHTHALMIC SOLUTIONS; OPHTHALMOLOGY; PHARMACEUTICAL SERVICES; PRACTICE PATTERNS, PHYSICIANS';

EID: 77957266668     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2010.05.005     Document Type: Article

References (69)

1. J.J. Needle, R. Petchey, and J.G. Lawrenson A survey of the scope of therapeutic practice by UK optometrists and their attitudes to an extended prescribing role Ophthalmic Physiol Opt 28 3 2008 193 203 (Pubitemid 351569411)
2. I. Sketris, E. Ingram, and H. Lummis Optimal prescribing and medication use in Canada: challenges and opportunities http://www.healthcouncilcanada.ca/ docs/rpts/2007/pharma/HCC-Symposium-Paper-FA.pdf accessed April 3, 2010 May 2007 Health Council of Canada Toronto
3. D.M. Krumholz, S.D. Jaanus, and R.L. Urquidi Prescribing patterns of optometrists newly licensed in therapeutic drug use in New York State Optometry 72 5 2001 292 298
4. I. Goldberg, G. Moloney, and P. McCluskey Topical ophthalmic medications: what potential for systemic side effects and interactions with other medications? Med J Aust 189 7 2008 356 357
5. S. Schneeweiss, and J. Avorn A review of uses of health care utilization databases for epidemiologic research on therapeutics J Clin Epidemiol 58 4 2005 323 337 (Pubitemid 40601980)
6. B.C. Choi, and A.W. Pak A catalog of biases in questionnaires Prev Chronic Dis 2 1 2005 A13
7. C.Y. Lu Pharmacoepidemiologic research in Australia: challenges and opportunities for monitoring patients with rheumatic diseases Clin Rheumatol 28 4 2009 371 377
8. J.D. Stein, P. Ayyagari, and F.A. Sloan Rates of glaucoma medication utilization among persons with primary open-angle glaucoma, 1992 to 2002 Ophthalmology 115 8 2008 1315 1319
9. D.N. Bateman, R. Clark, and A. Azuara-Blanco The impact of new drugs on management of glaucoma in Scotland: observational study BMJ 323 7326 2001 1401 1402 (Pubitemid 33152493)
10. D.N. Bateman, R. Clark, and A. Azuara-Blanco The effects of new topical treatments on management of glaucoma in Scotland: an examination of ophthalmological health care Br J Ophthalmol 86 5 2002 551 554 (Pubitemid 34454502)
11. R. De Natale, E. Draghi, and M.T. Dorigo How prostaglandins have changed the medical approach to glaucoma and its costs: an observational study of 2228 patients treated with glaucoma medications Acta Ophthalmol Scand 82 4 2004 393 396 (Pubitemid 39199437)
12. J.D. Stein, F.A. Sloan, and P.P. Lee Rates of glaucoma medication utilization among older adults with suspected glaucoma, 1992 to 2002 Am J Ophthalmol 143 5 2007 870 872
13. S.M. Macleod, R. Clark, and J. Forrest A review of glaucoma treatment in Scotland 19942004 Eye (Lond) 22 2 2008 251 255 (Pubitemid 351266467)
14. C.G. Owen, I.M. Carey, and S. De Wilde The epidemiology of medical treatment for glaucoma and ocular hypertension in the United Kingdom: 1994 to 2003 Br J Ophthalmol 90 7 2006 861 868 (Pubitemid 43973997)
15. C. Baudouin, J.F. Rouland, and C. Le Pen Changes in medical and surgical treatments of glaucoma between 1997 and 2000 in France Eur J Ophthalmol 13 Suppl 4 2003 S53 S60
16. M.J. Walland Glaucoma treatment in Australia: changing patterns of therapy 19942003 Clin Experiment Ophthalmol 32 6 2004 590 596
17. R. van der Valk, J.S. Schouten, and C.A. Webers The impact of a nationwide introduction of new drugs and a treatment protocol for glaucoma on the number of glaucoma surgeries J Glaucoma 14 3 2005 239 242 (Pubitemid 40677264)
18. I. Kaiserman, N. Kaiserman, and S. Nakar The effect of combination pharmacotherapy on the prescription trends of glaucoma medications J Glaucoma 14 2 2005 157 160 (Pubitemid 40389186)
19. R. Rachmiel, G.E. Trope, and M.L. Chipman Effect of medical therapy on glaucoma filtration surgery rates in Ontario Arch Ophthalmol 124 10 2006 1472 1477 (Pubitemid 44537149)
20. F.A. Knox, M. Barry, and B. McGowan The rising cost of glaucoma drugs in Ireland 19962003 Br J Ophthalmol 90 2 2006 162 165 (Pubitemid 43163844)
21. P.A. Kenigsberg Changes in medical and surgical treatments of glaucoma between 1997 and 2003 in France Eur J Ophthalmol 17 4 2007 521 527
22. G.F. Schwartz, and H.A. Quigley Adherence and persistence with glaucoma therapy Surv Ophthalmol 53 Supp11 2008 S57 S68
23. P.P. Lee, J.G. Walt, and T.H. Chiang A gap analysis approach to assess patient persistence with glaucoma medication Am J Ophthalmol 144 4 2007 520 524
24. J.H. Gurwitz, R.J. Glynn, and M. Monane Treatment for glaucoma: adherence by the elderly Am J Public Health 83 5 1993 711 716 (Pubitemid 23143002)
25. J.H. Gurwitz, S.M. Yeomans, and R.J. Glynn Patient noncompliance in the managed care setting The case of medical therapy for glaucoma Med Care 36 3 1998 357 369
26. R. Platt, G. Reardon, and E. Mozaffari Observed time between prescription refills for newer ocular hypotensive agents: the effect of bottle size Am J Ophthalmol 137 1 Suppl 2004 S17 S23 (Pubitemid 38091631)
27. A.L. Robin, and D. Covert Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology 112 5 2005 863 868 (Pubitemid 40631506)
28. J.G. Walt, J.T. Wilensky, and R. Fiscella Refill rates and budget impact of glaucoma lipid therapy: a retrospective database analysis Clin Drug Investig 27 12 2007 819 825 (Pubitemid 350145435)
29. C.E. Traverso, J.G. Walt, and L.S. Stern Pharmacotherapy compliance in patients with ocular hypertension or primary open-angle glaucoma J Ocul Pharmacol Ther 25 1 2009 77 82
30. M.J. Bhosle, G. Reardon, and F.T. Camacho Medication adherence and health care costs with the introduction of latanoprost therapy for glaucoma in a Medicare managed care population Am J Geriatr Pharmacother 5 2 2007 100 111 (Pubitemid 47264113)
31. H.A. Quigley, D.S. Friedman, and S.R. Hahn Evaluation of practice patterns for the care of open-angle glaucoma compared with claims data: the Glaucoma Adherence and Persistency Study Ophthalmology 114 9 2007 1599 1606
32. D.S. Friedman, H.A. Quigley, and L. Gelb Using pharmacy claims data to study adherence to glaucoma medications: methodology and findings of the Glaucoma Adherence and Persistency Study (GAPS) Invest Ophthalmol Vis Sci 48 11 2007 5052 5057 (Pubitemid 351260915)
33. J. Wilensky, R.G. Fiscella, and A.M. Carlson Measurement of persistence and adherence to regimens of IOP-lowering glaucoma medications using pharmacy claims data Am J Ophthalmol 141 1 Suppl 2006 S28 S33 (Pubitemid 43028477)
34. S.S. Jayawant, M.J. Bhosle, and R.T. Anderson Depressive symptomatology, medication persistence, and associated healthcare costs in older adults with glaucoma J Glaucoma 16 6 2007 513 520
35. G. Reardon, G.F. Schwartz, and E. Mozaffari Patient persistency with topical ocular hypotensive therapy in a managed care population Am J Ophthalmol 137 1 Suppl 2004 S3 S12 (Pubitemid 38091629)
36. G. Reardon, G.F. Schwartz, and E. Mozaffari Patient persistency with pharmacotherapy in the management of glaucoma Eur J Ophthalmol 13 Suppl 4 2003 S44 S52
37. G. Reardon, G.F. Schwartz, and E. Mozaffari Patient persistency with ocular prostaglandin therapy: a population-based, retrospective study Clin Ther 25 4 2003 1172 1185 (Pubitemid 36532585)
38. F.T. Shaya, C.D. Mullins, and W. Wong Discontinuation rates of topical glaucoma medications in a managed care population Am J Manag Care 8 10 Suppl 2002 S271 S277 (Pubitemid 34918728)
39. S. Dasgupta, V. Oates, and B.K. Bookhart Population-based persistency rates for topical glaucoma medications measured with pharmacy claims data Am J Manag Care 8 10 Suppl 2002 S255 S261 (Pubitemid 34918726)
40. J.J. Spooner, M.F. Bullano, and L.I. Ikeda Rates of discontinuation and change of glaucoma therapy in a managed care setting Am J Manag Care 8 10 Suppl 2002 S262 S270
41. G.F. Schwartz, G. Reardon, and E. Mozaffari Persistency with latanoprost or timolol in primary open-angle glaucoma suspects Am J Ophthalmol 137 1 Suppl 2004 S13 S16 (Pubitemid 38091630)
42. C.G. Owen, I.M. Carey, and S. de Wilde Persistency with medical treatment for glaucoma and ocular hypertension in the United Kingdom: 19942005 Eye (Lond) 23 5 2009 1098 1110
43. A. Lafuma, and G. Berdeaux Costs and effectiveness of travoprost versus a dorzolamide + timolol fixed combination in first-line treatment of glaucoma: analysis conducted on the United Kingdom General Practitioner Research Database Curr Med Res Opin 23 12 2007 3009 3016
44. P. Denis, A. Lafuma, and G. Berdeaux Costs and persistence of alpha-2 adrenergic agonists versus carbonic anhydrase inhibitors, both associated with prostaglandin analogues, for glaucoma as recorded by The United Kingdom General Practitioner Research Database Clin Ophthalmol 2 2 2008 321 329
45. R. De Natale, A. Lafuma, and G. Berdeaux Cost effectiveness of travoprost versus a fixed combination of latanoprost/timolol in patients with ocular hypertension or glaucoma: analysis based on the UK general practitioner research database Clin Drug Investig 29 2 2009 111 120
46. A. Lafuma, and G. Berdeaux Costs and persistence of carbonic anhydrase inhibitor versus alpha-2 agonists, associated with beta-blockers, in glaucoma and ocular hypertension: an analysis of the UK-GPRD database Curr Med Res Opin 24 5 2008 1519 1527 (Pubitemid 351741585)
47. A. Lafuma, C. Laurendeau, and G. Berdeaux Costs and persistence of brimonidine versus brinzolamide in everyday glaucoma care: an analysis conducted on the UK General Practitioner Research Database J Med Econ 11 3 2008 485 497
48. E.J. Higginbotham, J. Hansen, and E.J. Davis Glaucoma medication persistence with a fixed combination versus multiple bottles Curr Med Res Opin 25 10 2009 2543 2547
49. B.L. Nordstrom, D.S. Friedman, and E. Mozaffari Persistence and adherence with topical glaucoma therapy Am J Ophthalmol 140 4 2005 598 606 (Pubitemid 41455298)
50. J.L. Rait, and M.A. Adena Persistency rates for prostaglandin and other hypotensive eyedrops: population-based study using pharmacy claims data Clin Experiment Ophthalmol 35 7 2007 602 611
51. G.F. Schwartz, R. Platt, and G. Reardon Accounting for restart rates in evaluating persistence with ocular hypotensives Ophthalmology 114 4 2007 648 652 (Pubitemid 46483699)
52. T.J. Zimmerman, S.R. Hahn, and L. Gelb The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: changes in prescription patterns and patient persistence J Ocul Pharmacol Ther 25 2 2009 145 152
53. Z. Zhou, R. Althin, and B.S. Sforzolini Persistency and treatment failure in newly diagnosed open angle glaucoma patients in the United Kingdom Br J Ophthalmol 88 11 2004 1391 1394 (Pubitemid 39424716)
54. I. Goldberg, and M.A. Adena Co-prescribing of topical and systemic beta-blockers in patients with glaucoma: a quality use of medicine issue in Australian practice Clin Experiment Ophthalmol 35 8 2007 700 705 (Pubitemid 350090525)
55. R.J. Valuck, J.I. Perlman, and C. Anderson Co-prescribing of medications used to treat obstructive lung disease, congestive heart failure and depression among users of topical beta blockers: estimates from three US Veterans Affairs Medical Centers Pharmacoepidemiol Drug Saf 10 6 2001 511 516 (Pubitemid 34100779)
56. M. Houde, A.M. Castilloux, and D. Tingey Prescription of topical antiglaucoma agents for patients with contraindications to beta-blockers Can J Ophthalmol 38 6 2003 469 475 (Pubitemid 37465965)
57. S. Vinker, I. Kaiserman, and D.A. Waitman Prescription of ocular beta-blockers in patients with obstructive pulmonary disease: Does a central electronic medical record make a difference? Clin Drug Investig 26 9 2006 495 500 (Pubitemid 44253495)
58. I. Kaiserman, N. Kaiserman, and A. Elhayany Topical beta-blockers are not associated with an increased risk of treatment for depression Ophthalmology 113 7 2006 1077 1080 (Pubitemid 43947251)
59. D. Covert, and A.L. Robin Adjunctive glaucoma therapy use associated with travoprost, bimatoprost, and latanoprost Curr Med Res Opin 22 5 2006 971 976 (Pubitemid 43875566)
60. J.K. Schmier, D.W. Covert, and A.L. Robin Estimated first-year costs of prostaglandin analogs with/without adjunctive therapy for glaucoma management: a United States perspective Curr Med Res Opin 23 11 2007 2867 2875
61. J.K. Schmier, D.W. Covert, and A.L. Robin First-year treatment patterns among new initiators of topical prostaglandin analogs Curr Med Res Opin 25 4 2009 851 858
62. D.S. Friedman, S.R. Hahn, and L. Gelb Doctor-patient communication, health-related beliefs, and adherence in glaucoma results from the Glaucoma Adherence and Persistency Study Ophthalmology 115 8 2008 1320 1327
63. G.F. Schwartz, J. Tan, and S. Kotak Hyperemia-associated costs of medication changes in glaucoma patients treated initially with prostaglandin analogs J Ocul Pharmacol Ther 25 6 2009 555 561
64. S.K. Law, B.J. Song, and E. Fang Feasibility and efficacy of a mass switch from latanoprost to bimatoprost in glaucoma patients in a prepaid Health Maintenance Organization Ophthalmology 112 12 2005 2123 2130 (Pubitemid 41720990)
65. J.E. Martikainen, U. Hakkinen, and H. Enlund Adoption of new antiglaucoma drugs in Finland: impact of changes in copayment Clin Ther 29 11 2007 2468 2476 (Pubitemid 350298131)
66. J.C. Tsai, C.A. McClure, and S.E. Ramos Compliance barriers in glaucoma: a systematic classification J Glaucoma 12 5 2003 393 398
67. T.A. Gray, L.C. Orton, and D. Henson Interventions for improving adherence to ocular hypotensive therapy Cochrane Database Syst Rev 2 2009 CD006132
68. E. von Elm, D.G. Altman, and M. Egger The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies Ann Intern Med 147 8 2007 573 577 (Pubitemid 351664504)
69. C.Y. Lu Observational studies: a review of study designs, challenges and strategies to reduce confounding Int J Clin Pract 63 5 2009 691 697